PATIENTS archivos - Page 6 of 8 - European Migraine & Headache Alliance

Why are migraine patients skipping effective behavioral treatments?

MEDICAL COMMUNITY, News, PATIENTS / By EMHA

Effective behavioral treatments for migraine are being eschewed by a significant number of sufferers, according to a new study led by headache researchers at NYU School of Medicine. Researchers found that about half of migraine patients who were referred by a headache center for specific behavioral treatment did not follow through with therapy. This occurred […]

Why are migraine patients skipping effective behavioral treatments? Read More »

Diet and migraine

News, PATIENTS / By EMHA

How to take care of your diet if you suffer migraine 30th MAY 2018 If we pay attention to what we eat, we can contribute to keeping headaches as far away from our lives as possible. If you have migraine, you probably know that maintaining a healthy lifestyle and respecting food and sleep schedules are

Diet and migraine Read More »

Arnold Neuralgia/Recurrent occipital pain cause

MEDICAL COMMUNITY, News, PATIENTS / By EMHA

Recurrent, troublesome occipital pain associated with muscular tension is known as Arnold’s neuralgia, a strange condition. The condition of peripheral nerves can produce the pain of varying intensity as a reflex mechanism, depending on the degree of damage being considered. Some anatomical locations are often associated with these syndromes, with the exception of the occipital

Arnold Neuralgia/Recurrent occipital pain cause Read More »

Cluster headache: Galcanezumab

INDUSTRY, MEDICAL COMMUNITY, News, PATIENTS / By EMHA

Cluster headache: Galcanezumab Prevention of episodic cluster headache: Primary endpoint achieved in Phase 3 study 16/05/2018 Eli Lilly and Company announced that Galcanezumab met with the primary endpoint in a Phase 3 trial of episodic cluster headache patients, the statistically significant differences in reducing headache attacks. In weekly clusters compared to placebo during the weeks

Cluster headache: Galcanezumab Read More »

New Drug Offers Hope to Millions With Severe Migraines

INDUSTRY, News, PATIENTS / By EMHA

The first medicine designed to prevent migraines was approved by the Food and Drug Administration on Thursday, ushering in what many experts believe will be a new era in treatment for people who suffer the most severe form of these headaches. The drug, Aimovig, made by Amgen and Novartis, is a monthly injection with a

New Drug Offers Hope to Millions With Severe Migraines Read More »

Migraine and genetic

MEDICAL COMMUNITY, News, PATIENTS / By EMHA

Migraine and genetic Migraine is associated with a polygenic inheritance Migraines and genetic: A new study has found that some families are especially sensitive to Migraines and that genetics influences the type of migraine suffered by affected people. Migraine is a disease that has as its main symptom headache, throbbing, unilateral, accompanied by nausea or

Migraine and genetic Read More »

CGRP as the target of new migraine therapies

INDUSTRY, MEDICAL COMMUNITY, News, PATIENTS / By EMHA

CGRP as the target of new migraine therapies — successful translation from bench to clinic You can now download the document here: —–> CGRP as the target of new migraine therapies — successful translation from bench to clinic Treatment of migraine is on the cusp of a new era with the development of drugs that target

CGRP as the target of new migraine therapies Read More »

European Patients’ Rights Day, TODAY, April 18

Associations, News, PATIENTS, PATIENTS ASSOCIATIONS, POLICY MAKERS / By EMHA

Patients claim their right to participate in Decision about their Health Patients have the right to participate in making decisions about their health, either through patient organizations in public policies that affect them or through the sharing of information and consensus with their doctor, for example, about what treatment to follow. This is one of

European Patients’ Rights Day, TODAY, April 18 Read More »

New measures to avoid valproate exposure in pregnancy

INDUSTRY, MEDICAL COMMUNITY, News, PATIENTS / By EMHA

The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) has endorsed new measures to avoid exposure of babies to valproate medicines in the womb, because exposed babies are at high risk of malformations and developmental problems. The new measures include a ban on the use of such medicines for migraine or bipolar

New measures to avoid valproate exposure in pregnancy Read More »

Cluster Headache Awareness Day 2018 ( CHAD )

Events, INDUSTRY, News, PATIENTS, PATIENTS ASSOCIATIONS / By EMHA

CHAD organised together with the EMHA Cluster Headache Special Interest Group [CHSIG], which will be held on March 21st in Paris. The draft programme is attached. The theme for this year will be “ Shaping a painless future for Cluster Headache”. During the event different important topics regarding CH will be discussed such as personal

Cluster Headache Awareness Day 2018 ( CHAD ) Read More »

Why are migraine patients skipping effective behavioral treatments?

Diet and migraine

Arnold Neuralgia/Recurrent occipital pain cause

Cluster headache: Galcanezumab

New Drug Offers Hope to Millions With Severe Migraines

Migraine and genetic

CGRP as the target of new migraine therapies

European Patients’ Rights Day, TODAY, April 18

New measures to avoid valproate exposure in pregnancy

Cluster Headache Awareness Day 2018 ( CHAD )

MENU

LASTEST NEWS

Stigma survey press release

Talking Head Pain Podcast

Stigma survey

Migraine Day Of Action

SOCIAL

FOR YOU

Working together we can achieve a better future for all patients living with migraine.